How Much Does Healthcare Influence Longevity?

Medscape | May 13, 2019

Healthcare is only one of several factors that affect longevity in the United States, a new study reaffirms. Behavioral and social factors have much more influence.Robert Kaplan, PhD, and Arnold Milstein, MD, MPH, from Stanford University School of Medicine's Clinical Excellence Research Center in California, tested how much healthcare affects the risk for premature death using four different research methods and data sets.

Spotlight

Cardinal Health MedSync Advantage™ offers a new opportunity to drive greater medication adherence for your patients, while improving pharmacy operations and positively impacting the bottom line of your business.

Spotlight

Cardinal Health MedSync Advantage™ offers a new opportunity to drive greater medication adherence for your patients, while improving pharmacy operations and positively impacting the bottom line of your business.

Related News

MEDICAL DEVICES

AXENYA MERGES WITH HEALTHCO TO CREATE THE MOST ADVANCED HEALTH-TECH ECOSYSTEM IN THE REGION

Axenya Holdings Inc | August 04, 2022

AXENYA, a leading Latin-American digital health start-up company, and HealthCo, a premier data-intensive consulting firm and insurance broker, announce that they have reached an agreement to merge the companies into the leading corporate health-tech ecosystem in the Latin-American region. The combined companies will serve over 35,000 lives and have the capacity to deliver value across the entire healthcare journey. The companies expect to more than double that number in the coming year. All founding and operating teams at HealthCo and Axenya will remain in the company and as shareholders of the new company, which will operate under the Axenya brand. "The New Axenya marries the most advanced population data science with cutting edge, clinically proven, digital therapeutics", said Mariano García-Valiño, Founder of Axenya. "The combination creates an unbeatable ecosystem, where we can gather data to analyze large populations, identify care gaps and create perfectly targeted individual digital plans for each person, improving clinical metrics and reducing cost across the entire spectrum". Axenya, that started operations in 2020, offers software and hardware products that expand the doctor's toolbox, allows them to help their patients achieve higher standards of health and make the overall practice of medicine more personalized and precise. The company is the first member of the Digital Therapeutic Alliance in Latin America and the only company in the region with clinical research published in peer-reviewed journals. HealthCo is one of the most advanced data-intensive healthcare brokers in the region and approaching 90 corporate clients. Their proprietary data analytics result in consistent savings for their client base. The combination becomes a one stop shop to enable corporate clients to maximize quality and expense in all aspects of their healthcare needs: from population analytics, 24/7 monitoring and course correction, delivering individually selected next generation digital therapeutic tools and ultimately renegotiating fees with payors driven by the savings generated by its healthcare program. As a result, Axenya will deliver unparalleled clinical results, user satisfaction and cost savings. "We now have a company that can deliver results like nobody else in the market. Using a combination of software, technology, machine learning and behavioral and data science, Axenya can optimize the healthcare journey end-to-end, empowering companies and its employees with unbiased information, trusted guidance and high-value care, and delivering, at the same time, effective cost savings." Roberto Vianna, co-Founder of HealthCo In combination with this merger, Axenya received a capital injection, led by IGAH ventures, and with participation of NXTP, Big_Bets, Alexia, Axenya's founder Mariano Garcia-Valiño and several individual investors and employees. ABOUT AXENYA Axenya is a health technology company that seeks to connect Latin America with the future of medicine. With its digitally enhanced corporate health ecosystem, it offers and manages the most suitable healthcare plans in a digital, efficient and transparent fashion, protecting the employee's health, end to end, through all the journey. Integrating cutting edge software, hardware, artificial intelligence, intensive data-analysis and behavioral sciences, Axenya improves the efficiency in delivering health services, as well as expands the companies' toolbox and makes medicine more personal and precise, offering what is effectively a new care standard. The company delivers excellent patient satisfaction, superior clinic results and lower costs, improving the quality per dollar spent by companies while allowing access to modern medicine to all employees and dependents.

Read More

HEALTH TECHNOLOGY

Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio

Axonics, Inc. | August 18, 2022

Axonics, Inc. a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that in the last twelve months, the United States Patent and Trademark Office has granted eight patents and allowed four patent applications related to the company’s sacral neuromodulation technology. The patents and allowed applications are part of Axonics’ patent portfolio and represents technology internally developed by the company covering a range of subject matter that includes the Axonics external trial system, tined lead, implantable neurostimulator, clinician programmer, wireless charging system and patient remote control. “Axonics is committed to developing best-in-class technology to serve the unmet needs of the millions of adults suffering from incontinence. The volume, subject matter diversity, and breadth of these patents demonstrate the investment in innovation that Axonics continues to make in sacral neuromodulation technology,” Raymond W. Cohen, chief executive officer About Axonics Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas. Axonics sacral neuromodulation (SNM) systems provide adults suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries.

Read More

HEALTH TECHNOLOGY

Nanomix Enters into Distribution Agreement for the eLab System and Future New Products with BIOASIA PTE LTD in Singapore

Nanomix Corporation and BIOASIA PTE LTD. | August 24, 2022

Nanomix Corporation a leader in the development of mobile, affordable, point-of-care diagnostics, announced that it has entered into a distribution agreement with BIOASIA PTE LTD a medical diagnostics distributor located in Singapore. Bioasia will market and distribute the Nanōmix eLab® system in Singapore and Brunei, including the Nanōmix S1 Panel assay and future new test products for the eLab system. “We are pleased to introduce and give access to much needed, new diagnostics to our hospitals and customers. Sepsis and critical infections are a challenge in Singapore in the same way they are around the world. Our partnership with Nanomix will help us bring a unique option to our customers and the healthcare system in Singapore.” Henry Lim, Managing Director of Bioasia Thomas Schlumpberger, Chief Executive Officer of Nanomix, stated, “Nanomix is at the cusp of commercialization and continues to show early successes in executing upon our commercialization strategy. We are excited to see increased interest in our products especially in Asia, beginning in Singapore, which represents a significant and untapped growth opportunity for Nanomix.” John Hardesky, Chief Commercial Officer of Nanomix, stated, “Singapore has been ranked as one of the most efficient healthcare systems in the world for many years. The Nanōmix eLab® analyzer runs the S1 Panel assay rapidly, diagnosing critical infections including sepsis in 12 minutes which will undoubtedly lead to breakthroughs in earlier sepsis patient diagnosis.” Sepsis is a recognized global health crisis. Early identification and treatment are a need and a challenge for healthcare professionals around the globe. For many reasons, sepsis can be difficult to identify and is frequently under-diagnosed in the earliest stages. It affects as many as 50 million people every year, leading to approximately 11 million deaths annually. The Nanōmix eLab® system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanōmix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the S1 Panel Cartridge was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type. The assay runs on the eLab® Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration. About BIOASIA PTE LTD Bioasia was established in 2005 focusing on medical marketing and distribution of critical care products and monitoring equipment for patients requiring intensive care in intensive care settings. Our staff are professional biomedical engineers with knowledge of ISO13485. We work with medical professionals in hospital settings to ensure in-hospital equipment are at optimal working conditions for effective patient monitoring and results. Bioasia has represented various medical device companies in Singapore and Brunei markets since 2005. Bioasia is GDPMDS certified. About Nanomix Corporation Nanomix is developing mobile point-of-care diagnostics with its Nanōmix eLab® System platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company’s products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomix’s first assays address the need for faster diagnosis of critical infections including sepsis. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes.

Read More